SPINK4 Expression as a Predictive Biomarker for Radiolabeled Immune Modulator Therapy in Advanced Colorectal Cancer

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
• Preoperative chemotherapy and radiation therapy (CRT) combined with immune modulation are emerging treatments for advanced CRC.
• SPINK4 (protein serine peptidase inhibitor Kazal type 4) is implicated in cancer immune evasion and treatment resistance.

Purpose of the Study:

• To evaluate the association between SPINK4 expression and treatment efficacy of radiolabeled immune modulators in advanced CRC patients.
• To determine if SPINK4 can serve as a prognostic biomarker for this patient group.

Main Methods:

• Meta-analysis of studies investigating SPINK4 expression in advanced CRC.
• Assessment of treatment response to radiolabeled immune modulators in relation to SPINK4 levels.
• Correlation analysis between SPINK4 expression and objective response rates.

Main Results:

• A significant link was observed between high SPINK4 expression and a reduced objective response to radiolabeled immune modulators.
• Patients with low SPINK4 expression demonstrated more favorable treatment responses and sustained clinical improvement post-CRT.
• SPINK4 expression levels were identified as a potential negative prognostic biomarker.

Conclusions:

• Elevated SPINK4 expression is associated with poorer outcomes in advanced CRC patients treated with radiolabeled immune modulators.
• SPINK4 may predict resistance to this therapeutic approach, highlighting its role in treatment failure.
• Targeting SPINK4 or selecting patients based on its expression could personalize CRC treatment strategies.